期刊文献+
共找到6,286篇文章
< 1 2 250 >
每页显示 20 50 100
A Convenient Synthesis of the Substituted 2,3-Diarylindole the Potent Selective COX-2 Inhibitors
1
作者 WenHuiHU ZonRuGUO 《Chinese Chemical Letters》 SCIE CAS CSCD 2002年第4期296-298,共3页
Phenyl sulfone-containing 2, 3-diarylindole derivatives were designed and identified to be selective COX-2 inhibitors. A convenient synthetic route was also developed for the synthesis of the novel inhibitors.
关键词 Nonsteroidal anti-inflammatory drugs (NSAIDs) selective cox-2 inhibitors substituted 2 3-diarylindole pharmacophore.
下载PDF
Anti-cancer effects of COX-2 inhibitors and their correlation wit angiogenesis and invasion in gastric cancer 被引量:22
2
作者 Suo-LinFu Yun-LinWu Yong-PingZhang Min-MinQiao YingChen 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第13期1971-1974,共4页
AIM- To observe the anti-cancer effects of COX-2 inhibitors and investigate the relationship between COX-2 inhibitors and angiogenesis, infiltration or metastasis in SGC7901 cancer xenografts.METHODS: Thirty athymic m... AIM- To observe the anti-cancer effects of COX-2 inhibitors and investigate the relationship between COX-2 inhibitors and angiogenesis, infiltration or metastasis in SGC7901 cancer xenografts.METHODS: Thirty athymic mice xenograft models with human stomach cancer cell SGC7901 were established and divided randomly into 3 groups of 10 each. Sulindac, one non-specific COX inhibitor belonging to non-steroidal antiinflammatory drugs (a series of COX inhibitors known as NSAIDs) and celecoxib, one selective COX-2 inhibitor (known as SCIs) were orally administered to mice of treatment groups. Immunohistochemistry was used to examine the expression of PCNA, CD44v6 and microvessel density (MVD).Apoptosis was detected by using TUNEL assay.RESULTS: Tumors in sulindac and celecoxib groups were significantly smaller than those in control group from the second week after drug administration (P<0.01). In treatment group, the cell proliferation index was lower (P<0.05) and apoptosis index was higher (P<0.05) than those in control groups. Compared with the controls,microvessel density was reduced (P<0.01) and expression of CD44v6 on tumor cells was weakened (P<0.05) in treatment groups.CONCLUSION: COX-2 inhibitors have anticancer effects on gastric cancer. They play important roles in angiogenesis and infiltration or metastasis of stomach carcinoma. The anticancer effects of COX-2 inhibitors may include inducing apoptosis, suppressing proliferation, reducing angiogenesis and weakening invasiveness. 展开更多
关键词 抗肿瘤作用 cox-2 抑制剂 血管生成 胃癌 渗透作用
下载PDF
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and metaanalysis 被引量:2
3
作者 Yu-Qiong Xu Xiang Long +4 位作者 Ming Han Ming-Qiang Huang Jia-Fa Lu Xue-Dong Sun Wei Han 《World Journal of Clinical Cases》 SCIE 2021年第3期581-601,共21页
BACKGROUND Lung cancer is a major cause of death among patients,and non-small cell lung cancer(NSCLC)accounts for more than 80%of all lung cancers in many countries.AIM To evaluate the clinical benefit(CB)of COX-2 inh... BACKGROUND Lung cancer is a major cause of death among patients,and non-small cell lung cancer(NSCLC)accounts for more than 80%of all lung cancers in many countries.AIM To evaluate the clinical benefit(CB)of COX-2 inhibitors in patients with advanced NSCLC using systematic review.METHODS We searched the six electronic databases up until December 9,2019 for studies that examined the efficacy and safety of the addition of COX-2 inhibitors to chemotherapy for NSCLC.Overall survival(OS),progression free survival(PFS),1-year survival rate(SR),overall response rate(ORR),CB,complete response(CR),partial response(PR),stable disease(SD),and toxicities were measured with more than one outcome as their endpoints.Fixed and random effects models were used to calculate risk estimates in a meta-analysis.Potential publication bias was calculated using Egger’s linear regression test.Data analysis was performed using R software.RESULTS The COX-2 inhibitors combined with chemotherapy were not found to be more effective than chemotherapy alone in OS,progression free survival,1-year SR,CB,CR,and SD.However,there was a difference in overall response rate for patients with advanced NSCLC.In a subgroup analysis,significantly increased ORR results were found for celecoxib,rofecoxib,first-line treatment,and PR.For adverse events,the increase in COX-2 inhibitor was positively correlated with the increase in grade 3 and 4 toxicity of leukopenia,thrombocytopenia,and cardiovascular events.CONCLUSION COX-2 inhibitor combined with chemotherapy increased the total effective rate of advanced NSCLC with the possible increased risk of blood toxicity and cardiovascular events and had no effect on survival index. 展开更多
关键词 Non-small cell lung cancer cox-2 SURVIVAL Progression free survival Systematic review Randomized controlled trials
下载PDF
Health Related Quality of Life among Osteoarthritis Patients: A Comparison of Traditional Non-Steroidal Anti-Inflammatory Drugs and Selective COX-2 Inhibitors in the United Arab Emirates Using the SF-36
4
作者 Mohammed Hassanein Mohammed Shamssain Nageeb Hassan 《Pharmacology & Pharmacy》 2015年第4期232-240,共9页
Objectives: Osteoarthritis (OA) has a dramatic impact on patients’ health related quality of life (HRQoL). Chronic use of analgesics and anti-inflammatory medications for pain management may improve symptoms but on l... Objectives: Osteoarthritis (OA) has a dramatic impact on patients’ health related quality of life (HRQoL). Chronic use of analgesics and anti-inflammatory medications for pain management may improve symptoms but on long term may affect HRQoL negatively. The objective of the present study was to compare the impact of two different classes of analgesics, traditional non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclo-oxygenase-2 (COX-2) inhibitors on HRQoL among osteoarthritis patients using the SF-36 questionnaire. Methods: Clinic based cross-sectional study conducted at Al-Qassimi Hospital, Sharjah, United Arab Emirates (UAE), over a period of six months. Ethical Approval was obtained from the ethics committee at Al-Qassimi Clinical Research Center. Total of 200 osteoarthritis patients fulfilling the inclusion and exclusion criteria were involved in the study. Patients’ demographics were collected from their medical records. The Medical Outcome Study Short-Form 36 (SF-36) questionnaire was used to measure patients’ HRQoL. SF-36 data were scored using health outcomes scoring software 4.5. Results: Mean age of the subjects was 62.19 ± 9.81 years with females constituting 151 (75.5%) of the patients. In general, females scored lower in most of the HRQoL domains compared to males and there was significant difference between the two groups in the mental health (p = 0.005) & mental component (p = 0.042) domains. Compared to selective COX-2 inhibitors, patients on NSAIDs scored higher on all domains of SF-36 except physical functioning. There was significant difference in mental health domain for patients treated with NSAIDs (p = 0.02). Celecoxib was only better than NSAIDs in osteoarthritis patients with more than one musculoskeletal disorders in the domain of bodily pain (p = 0.009). Conclusion: NSAIDs-treated patients did not differ significantly from celecoxib-treated patients in all domains of the SF-36 except for the mental health domain. 展开更多
关键词 OSTEOARTHRITIS Health Related Quality of Life Short Form-36 TRADITIONAL NONSTEROIDAL ANTI-INFLAMMATORY Drugs Selective cox-2 inhibitors
下载PDF
NSAIDs and the Gastrointestinal Tract: will COX-2 Inhibitors Make this a thing of the Past?
5
作者 ProfessorCJHawkey 《胃肠病学》 2000年第B08期22-23,共2页
Aspirin has been marketed for just over 100 years and for, an evolving set of clinical indications, has been the world's first and most successful mass marketed pharmaceutical compound. However, by 1937 it was cle... Aspirin has been marketed for just over 100 years and for, an evolving set of clinical indications, has been the world's first and most successful mass marketed pharmaceutical compound. However, by 1937 it was clear that aspirin could cause acute gastric erosions and chronic ulcers. Attempts to develop aspirin like compounds that would avoid of aspirin's topical toxicity did not result in avoidance of the same side effects. This is probably because aspirin and non-aspirin NSAIDs inhibit prostaglandin synthesis, a central component of both their therapeutic and toxic activity. 展开更多
关键词 NSAIDS 胃十二指肠疾病 cox-2 抑制作用 胃溃疡 慢性溃疡
全文增补中
Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure 被引量:1
6
作者 Petra Grubić Rotkvić Luka Rotkvić +1 位作者 Ana Đuzel Čokljat Maja Cigrovski Berković 《World Journal of Cardiology》 2024年第8期448-457,共10页
BACKGROUND Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)have shown efficacy in reducing heart failure(HF)burden in a very heterogeneous groups of patients,raising doubts about some contemporary assumptions... BACKGROUND Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)have shown efficacy in reducing heart failure(HF)burden in a very heterogeneous groups of patients,raising doubts about some contemporary assumptions of their mechanism of action.We previously published a prospective observational study that evaluated mechanisms of action of SGLT2i in patients with type 2 diabetes who were in HF stages A and B on dual hypoglycemic therapy.Two groups of patients were included in the study:the ones receiving SGLT2i as an add-on agent to metformin and the others on dipeptidyl peptidase-4 inhibitors as an add-on to metformin due to suboptimal glycemic control.AIM To evaluate the outcomes regarding natriuretic peptide,oxidative stress,inflammation,blood pressure,heart rate,cardiac function,and body weight.METHODS The study outcomes were examined by dividing each treatment arm into two subgroups according to baseline parameters of global longitudinal strain(GLS),N-terminal pro-brain natriuretic peptide,myeloperoxidase(MPO),high-sensitivity C-reactive protein(hsCRP),and systolic and diastolic blood pressure.To evaluate the possible predictors of observed changes in the SGLT2i arm during follow-up,a rise in stroke volume index,body mass index(BMI)decrease,and lack of heart rate increase,linear regression analysis was performed.RESULTS There was a greater reduction of MPO,hsCRP,GLS,and blood pressure in the groups with higher baseline values of mentioned parameters irrespective of the therapeutic arm after 6 months of follow-up.Significant independent predictors of heart rate decrease were a reduction in early mitral inflow velocity to early diastolic mitral annular velocity at the interventricular septal annulus ratio and BMI,while the predictor of stroke volume index increase was SGLT2i therapy itself.CONCLUSION SGLT2i affect body composition,reduce cardiac load,improve diastolic/systolic function,and attenuate the sympathetic response.Glycemic control contributes to the improvement of heart function,blood pressure control,oxidative stress,and reduction in inflammation. 展开更多
关键词 Sodium-dependent glucose transporter 2 inhibitors Dipeptidyl peptidase-4 inhibitors Type 2 diabetes mellitus Heart failure Diabetic cardiomyopathy Cardiovascular disease
下载PDF
Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus:A real-world experience 被引量:1
7
作者 Lubna Islam Dhanya Jose +3 位作者 Mohammed Alkhalifah Dania Blaibel Vishnu Chandrabalan Joseph M Pappachan 《World Journal of Diabetes》 SCIE 2024年第3期463-474,共12页
BACKGROUND Sodium glucose cotransporter-2 inhibitors(SGLT-2i)are a class of drugs with modest antidiabetic efficacy,weight loss effect,and cardiovascular benefits as proven by multiple randomised controlled trials(RCT... BACKGROUND Sodium glucose cotransporter-2 inhibitors(SGLT-2i)are a class of drugs with modest antidiabetic efficacy,weight loss effect,and cardiovascular benefits as proven by multiple randomised controlled trials(RCTs).However,real-world data on the comparative efficacy and safety of individual SGLT-2i medications is sparse.AIM To study the comparative efficacy and safety of SGLT-2i using real-world clinical data.METHODS We evaluated the comparative efficacy data of 3 SGLT-2i drugs(dapagliflozin,canagliflozin,and empagliflozin)used for treating patients with type 2 diabetes mellitus.Data on the reduction of glycated hemoglobin(HbA1c),body weight,blood pressure(BP),urine albumin creatinine ratio(ACR),and adverse effects were recorded retrospectively.RESULTS Data from 467 patients with a median age of 64(14.8)years,294(62.96%)males and 375(80.5%)Caucasians were analysed.Median diabetes duration was 16.0(9.0)years,and the duration of SGLT-2i use was 3.6(2.1)years.SGLT-2i molecules used were dapagliflozin 10 mg(n=227;48.6%),canagliflozin 300 mg(n=160;34.3%),and empagliflozin 25 mg(n=80;17.1).Baseline median(interquartile range)HbA1c in mmol/mol were:dapagliflozin-78.0(25.3),canagliflozin-80.0(25.5),and empagliflozin-75.0(23.5)respectively.The respective median HbA1c reduction at 12 months and the latest review(just prior to the study)were:66.5(22.8)&69.0(24.0),67.0(16.3)&66.0(28.0),and 67.0(22.5)&66.5(25.8)respectively(P<0.001 for all comparisons from baseline).Significant improvements in body weight(in kilograms)from baseline to study end were noticed with dapagliflozin-101(29.5)to 92.2(25.6),and canagliflozin 100(28.3)to 95.3(27.5)only.Significant reductions in median systolic and diastolic BP,from 144(21)mmHg to 139(23)mmHg;(P=0.015),and from 82(16)mmHg to 78(19)mmHg;(P<0.001)respectively were also observed.A significant reduction of microalbuminuria was observed with canagliflozin only[ACR 14.6(42.6)at baseline to 8.9(23.7)at the study end;P=0.043].Adverse effects of SGLT-2i were as follows:genital thrush and urinary infection-20(8.8%)&17(7.5%)with dapagliflozin;9(5.6%)&5(3.13%)with canagliflozin;and 4(5%)&4(5%)with empagliflozin.Diabetic ketoacidosis was observed in 4(1.8%)with dapagliflozin and 1(0.63%)with canagliflozin.CONCLUSION Treatment of patients with SGLT-2i is associated with statistically significant reductions in HbA1c,body weight,and better than those reported in RCTs,with low side effect profiles.A review of large-scale real-world data is needed to inform better clinical practice decision making. 展开更多
关键词 Sodium glucose cotransporter-2 inhibitors Empagliflozin Canagliflozin DAPAGLIFLOZIN Type 2 diabetes mellitus Cardiovascular disease Albumin creatinine ratio DIABESITY
下载PDF
Sodium-Glucose Cotransporter-2 Inhibitors: Who, When & How? Guidance for Use from a Multidisciplinary Practical Approach
8
作者 Khalifa Abdullah Magdy ElSharkawy +6 位作者 Emad R. Issak Ahmed Shawky ElSerafy Samah Idris Ahmed Bendary Haytham Reda Badr May Shehata Ashraf Reda 《International Journal of Clinical Medicine》 CAS 2024年第9期413-435,共23页
Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) have transformed diabetes management by targeting renal glucose reabsorption. Designed initially as antidiabetic agents, their ability to lower blood gluco... Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) have transformed diabetes management by targeting renal glucose reabsorption. Designed initially as antidiabetic agents, their ability to lower blood glucose levels independently of insulin is well-documented. Beyond glycemic control, emerging research has unveiled their profound cardiorenal benefits. By inhibiting SGLT-2 protein, these drugs enhance glucose excretion in urine, reducing blood glucose levels. This mechanism has translated into significant cardiovascular and renal protection, establishing SGLT-2 inhibitors as pivotal in managing not only diabetes but also cardiovascular and renal diseases. Recent studies have illuminated the broader therapeutic potential of SGLT-2 inhibitors beyond diabetes. Evidence indicates their efficacy in managing heart failure, chronic kidney disease (CKD), and cardiovascular complications in individuals with or without diabetes. This expanded therapeutic landscape has catalyzed a paradigm shift in SGLT-2 inhibitor use, positioning them as key agents in the cardiorenal metabolic continuum. Moreover, their role in the secondary prevention of cardiovascular events and slowing CKD progression in T2DM patients has garnered considerable attention. This consensus-based review aims to offer practical guidance in an algorithmic approach to primary care healthcare professionals to optimize SGLT-2 inhibitors utilization and maximize their benefits. The review seeks to empower clinicians to effectively manage patients who may benefit from SGLT-2 inhibitor therapy by addressing common initiation barriers and optimizing treatment strategies. Additionally, it aims to raise awareness among primary care physicians regarding the multifaceted benefits of these medications and overcome clinical inertia in their adoption into routine clinical practice. 展开更多
关键词 Sodium-Glucose Cotransporter-2 inhibitors Cardiorenal Benefits Therapeutic Potential Cardiovascular Protection Primary Care Optimization
下载PDF
Sodium glucose cotransporter-2 inhibitors and heart disease:Current perspectives
9
作者 Sunetra Mondal Subhodip Pramanik +2 位作者 Vibhu Ranjan Khare Cornelius James Fernandez Joseph M Pappachan 《World Journal of Cardiology》 2024年第5期240-259,共20页
Sodium glucose cotransporter-2 inhibitors(SGLT-2i)are antidiabetic medications with remarkable cardiovascular(CV)benefits proven by multiple randomised controlled trials and real-world data.These drugs are also useful... Sodium glucose cotransporter-2 inhibitors(SGLT-2i)are antidiabetic medications with remarkable cardiovascular(CV)benefits proven by multiple randomised controlled trials and real-world data.These drugs are also useful in the prevention of CV disease(CVD)in patients with diabetes mellitus(DM).Although DM as such is a huge risk factor for CVD,the CV benefits of SGLT-2i are not just because of antidiabetic effects.These molecules have proven beneficial roles in prevention and management of nondiabetic CVD and renal disease as well.There are various molecular mechanisms for the organ protective effects of SGLT-2i which are still being elucidated.Proper understanding of the role of SGLT-2i in prevention and management of CVD is important not only for the cardiologists but also for other specialists caring for various illnesses which can directly or indirectly impact care of heart diseases.This clinical review compiles the current evidence on the rational use of SGLT-2i in clinical practice. 展开更多
关键词 SGLT2 inhibitors SGLT2i Cardiovascular disease Heart failure Atherosclerotic cardiovascular disease Diabetic kidney disease
下载PDF
BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition
10
作者 Yu Meng Hui-Yan Sun +7 位作者 Yi He Qian Zhou Yi-Huang Liu Hui Su Ming-Zhu Yin Fu-Rong Zeng Xiang Chen Guang-Tong Deng 《Military Medical Research》 SCIE CAS CSCD 2024年第4期620-624,共5页
Dear Editor,Ferroptosis,an iron-dependent form of cell death driven by overwhelming lipid peroxidation,represents a vulnerability in cancers,and therapeutic strategies to further potentiate ferroptosis hold great pote... Dear Editor,Ferroptosis,an iron-dependent form of cell death driven by overwhelming lipid peroxidation,represents a vulnerability in cancers,and therapeutic strategies to further potentiate ferroptosis hold great potential for melanoma treatment. 展开更多
关键词 MELANOMA Bromodomain and extra terminal domain(BET)inhibitor Ferroptosis Cell death AKR1C2 IMMUNOTHERAPY
下载PDF
Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure
11
作者 Mohamed H Laimoud Ismail R Raslan 《World Journal of Cardiology》 2024年第11期665-668,共4页
Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)have been increa-singly used with proven efficacy in patients with heart failure(HF),regardless of diabetes status.GrubićRotkvićet al recently published an obse... Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)have been increa-singly used with proven efficacy in patients with heart failure(HF),regardless of diabetes status.GrubićRotkvićet al recently published an observational study on SGLT2i therapy in patients with type 2 diabetes mellitus and asymptomatic HF.They found that the use of SGLT2i led to reduced cardiac load and improved cardiovascular performance,reinforcing the evolving paradigm that SGLT2i are not merely glucose-lowering agents but are integral to the broader management of cardiovascular risk in patients with type 2 diabetes mellitus.The study by GrubićRotkvićet al contributes to the growing body of literature supporting the early use of SGLT2i in patients with diabetic cardiomyopathy,offering a potential strategy to mitigate the progression of HF.Future larger studies should be con-ducted to confirm these findings,and explore the long-term cardiovascular bene-fits of SGLT2i,particularly in asymptomatic patients at risk of developing HF. 展开更多
关键词 Heart failure Cardiovascular risk Diabetes mellitus MORTALITY Sodiumdependent glucose transporter 2 inhibitors
下载PDF
SGLT2 inhibitors in the prevention of diabetic cardiomyopathy:Targeting the silent threat
12
作者 Panayotis K Vlachakis Panagiotis Theofilis Dimitris Tousoulis 《World Journal of Cardiology》 2024年第11期669-672,共4页
Heart failure(HF)is a major global health challenge,particularly among indi-viduals with type 2 diabetes mellitus(T2DM),who are at significantly higher risk of developing HF.Diabetic cardiomyopathy,a unique form of he... Heart failure(HF)is a major global health challenge,particularly among indi-viduals with type 2 diabetes mellitus(T2DM),who are at significantly higher risk of developing HF.Diabetic cardiomyopathy,a unique form of heart disease,often progresses silently until advanced stages.Recent research has focused on sodium-dependent glucose transporter 2 inhibitors(SGLT2i),originally developed for hyperglycemia,which have shown potential in reducing cardiovascular risks,including HF hospitalizations,irrespective of diabetic status.In this editorial we comment on the article by GrubićRotkvićet al published in the recent issue of the World Journal of Cardiology.The investigators examined the effects of SGLT2i on myocardial function in T2DM patients with asymptomatic HF,finding significant improvements in stroke volume index and reductions in systemic vascular resis-tance,suggesting enhanced cardiac output.Additionally,SGLT2i demonstrated anti-inflammatory and antioxidant effects,as well as blood pressure reduction,though the study’s limitations—such as small sample size and observational design—necessitate larger randomized trials to confirm these findings.The study underscores the potential of early intervention with SGLT2i in preventing HF progression in T2DM patients. 展开更多
关键词 Sodium-dependent glucose transporter 2 inhibitor Diabetes mellitus Heart failure PATHOPHYSIOLOGY Inflammation Oxidative stress
下载PDF
Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients
13
作者 Yan-Xi Zhang Hai-Sheng Hu Bao-Qing Sun 《World Journal of Cardiology》 2024年第10期611-615,共5页
We comment on an article by GrubićRotkvićet al published in the recent issue of the World Journal of Cardiology.We specifically focused on possible factors affecting the therapeutic effectiveness of sodium-dependent g... We comment on an article by GrubićRotkvićet al published in the recent issue of the World Journal of Cardiology.We specifically focused on possible factors affecting the therapeutic effectiveness of sodium-dependent glucose transporter inhibitors(SGLT2i)in patients with type 2 diabetes mellitus(T2DM)and their impact on comorbidities.SGLT2i inhibits SGLT2 in the proximal tubules of the kidneys,lowering blood glucose levels by inhibiting glucose reabsorption by the kidneys and causing excess glucose to be excreted in the urine.Previous studies have demonstrated a role of SGLT2i in cardiovascular function in patients with diabetes who take metformin but still have poor glycemic control.In addition,SGLT2i has been shown to be effective in anti-apoptosis,weight loss,and cardiovascular protection.Accordingly,it is feasible to treat patients with T2DM with cardiovascular or renal diseases using SGLT2i. 展开更多
关键词 Sodium-dependent glucose transporter inhibitors Type 2 diabetes mellitus Heart failure Treatment Cardiovascular disease
下载PDF
Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes:A systematic review with multiple network meta-regressions
14
作者 Jing-Jing Zhu John P H Wilding Xiao-Song Gu 《World Journal of Diabetes》 SCIE 2024年第10期2135-2146,共12页
BACKGROUND Glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are associated with significant cardiovascular benefit in type 2 diabetes(T2D).However,GLP-1RA or SGL... BACKGROUND Glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are associated with significant cardiovascular benefit in type 2 diabetes(T2D).However,GLP-1RA or SGLT-2I alone may not improve some cardiovascular outcomes in patients with prior cardiovascular co-morbidities.AIM To explore whether combining GLP-1RA and SGLT-2I can achieve additional benefit in preventing cardiovascular diseases in T2D.METHODS The systematic review was conducted according to PRISMA recommendations.The protocol was registered on PROSPERO(ID:42022385007).A total of 107049 participants from eligible cardiovascular outcomes trials of GLP-1RA and SGLT-2I were included in network meta-regressions to estimate cardiovascular benefit of the combination treatment.Effect modification of prior myocardial infarction(MI)and heart failure(HF)was also explored to provide clinical insight as to when the INTRODUCTION The macro-and micro-vascular benefits of glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are independent of their glucose-lowering effects[1].In patients with type 2 diabetes(T2D),the major cardiovascular outcome trials(CVOT)showed that dipeptidyl peptidase-4 inhibitors(DPP-4I)did not improve cardiovascular outcomes[2],whereas cardiovascular benefit of GLP-1RA or SGLT-2I was significant[3,4].Further subgroup analyses indicated that the background cardiovascular risk should be considered when examining the cardiovascular outcomes of these newer glucose-lowering medications.For instance,prevention of major adverse cardiovascular events(MACE)was only seen in those patients with baseline atherosclerotic cardiovascular disease[3,4].Moreover,a series of CVOT conducted in patients with heart failure(HF)have demonstrated that(compared with placebo)SGLT-2I significantly reduced risk of hospitalization for HF or cardiovascular death,irrespective of their history of T2D[5-8].However,similar cardiovascular benefits were not observed in those with myocardial infarction(MI)[9,10].Cardiovascular co-morbidities are not only approximately twice as common but are also associated with dispropor-tionately worse cardiovascular outcomes in patients with T2D,compared to the general population[11].Therefore,it is of clinical importance to investigate whether the combination treatment of GLP-1RA and SGLT-2I could achieve greater cardiovascular benefit,particularly when considering patients with cardiovascular co-morbidities who may not gain sufficient cardiovascular protection from the monotherapies.This systematic review with multiple network meta-regressions was mainly aimed to explore whether combining GLP-1RA and SGLT-2I can provide additional cardiovascular benefit in T2D.Cardiovascular outcomes of these newer antidiabetic medications were also estimated under effect modification of prior cardiovascular diseases.This was to provide clinical insight as to when the combination treatment might be prioritized. 展开更多
关键词 Type 2 diabetes Glucagon-like peptide-1 receptor agonist Sodium-glucose co-transporter-2 inhibitor Combination treatment Cardiovascular outcome Systematic review Network meta-regression
下载PDF
In Silico Screening of Potential Inhibitors against dPLA2 from Named Chinese Herbs for Identification of Compounds with Antivenom Effects Due to Deinagkistrodon acutus Snake Bites
15
作者 Xingyang Xiao Mengyi Lai +3 位作者 Zechang Rao Jianzhong Huang Yiwei Xie Hongbin Zhang 《American Journal of Molecular Biology》 CAS 2024年第3期107-125,共19页
Phospholipase A2 (PLA2) is the key enzyme to the venom from Deinagkistrodon acutus which is one of the highly venomous snakes in China. In addition to being a catalyst for the hydrolysis of phospholipases A2 from snak... Phospholipase A2 (PLA2) is the key enzyme to the venom from Deinagkistrodon acutus which is one of the highly venomous snakes in China. In addition to being a catalyst for the hydrolysis of phospholipases A2 from snake venom, its well known that it possesses a broad spectrum of pharmacological activities, such as myotoxicity, neurotoxicity, cardiotoxicity, and hemolytic, anticoagulant and antiplatelet activities. However, snakebites are not efficiently treated by conventional serum therapy. Acute wounds can still cause poisoning and death. In order to find effective inhibitors of Deinagkistrodon venom acid phospholipase A2 (dPLA2), we obtained 385 compounds in 9 Chinese herbs from the TCMSP. These compounds were further performed to virtual screen using in silico tools like ADMET analysis, molecular docking and molecular dynamics (MD) simulation. After Pharmacokinetics analysis, we found 7 candidate compounds. Besides, analysis of small molecule interactions with dPLA2 confirmed that the amino acid residues HIS47 and GLY29 are key targets. Because they bind not only to the natural substrate phosphatidylcholine and compounds known for having inhibitory functions, but also for combining with potential antidote molecules in Chinese herbal medicine. This study is the first to report experience with virtual screening for possible inhibitor of dPLA2, such as the interaction spatial structure, binding energy and binding interaction analysis, these experiences not only provide reference for further experimental research, but also have a guideline for the study of drug molecular mechanism of action. 展开更多
关键词 Chinese Herbal Medicine Phospholipase A2 inhibitor Molecular Docking Molecular Mechanism
下载PDF
Sodium-glucose cotransporter-2 inhibitors protect tissues via cellular and mitochondrial pathways:Experimental and clinical evidence
16
作者 Raúl Lelio Sanz Sebastián García Menéndez +2 位作者 Felipe Inserra Leon Ferder Walter Manucha 《World Journal of Experimental Medicine》 2024年第2期46-52,共7页
Mitochondrial dysfunction is a key driver of cardiovascular disease(CVD)in metabolic syndrome and diabetes.This dysfunction promotes the production of reactive oxygen species(ROS),which cause oxidative stress and infl... Mitochondrial dysfunction is a key driver of cardiovascular disease(CVD)in metabolic syndrome and diabetes.This dysfunction promotes the production of reactive oxygen species(ROS),which cause oxidative stress and inflammation.Angiotensin II,the main mediator of the renin-angiotensin-aldosterone system,also contributes to CVD by promoting ROS production.Reduced activity of sirtuins(SIRTs),a family of proteins that regulate cellular metabolism,also worsens oxidative stress.Reduction of energy production by mitochondria is a common feature of all metabolic disorders.High SIRT levels and 5’adenosine monophosphate-activated protein kinase signaling stimulate hypoxia-inducible factor 1 beta,which promotes ketosis.Ketosis,in turn,increases autophagy and mitophagy,processes that clear cells of debris and protect against damage.Sodiumglucose cotransporter-2 inhibitors(SGLT2i),a class of drugs used to treat type 2 diabetes,have a beneficial effect on these mechanisms.Randomized clinical trials have shown that SGLT2i improves cardiac function and reduces the rate of cardiovascular and renal events.SGLT2i also increase mitochondrial efficiency,reduce oxidative stress and inflammation,and strengthen tissues.These findings suggest that SGLT2i hold great potential for the treatment of CVD.Furthermore,they are proposed as anti-aging drugs;however,rigorous research is needed to validate these preliminary findings. 展开更多
关键词 Sodium-glucose cotransporter-2 inhibitors Cardiovascular diseases SIRTUINS Oxidative stress INFLAMMATION Mitochondrial dysfunction
下载PDF
Clinical Use of COX-2 Inhibitors Containing Quinoline Heterocycle as a Selective Therapeutic Agents for Complementary Medicine
17
作者 Megha P.Ambatkar Nilesh R.Rarokar Pramod B.Khedekar 《Clinical Complementary Medicine and Pharmacology》 2023年第3期60-77,共18页
Inflammation represents an initial response of immune system and is involved in a number of biochemical inci-dents.Such incidents may multiply and further develop the provocative response.Over the past 15 years,variou... Inflammation represents an initial response of immune system and is involved in a number of biochemical inci-dents.Such incidents may multiply and further develop the provocative response.Over the past 15 years,various classes of secondary metabolites that were isolated from plant and marine sources have been described as natural cyclooxygenase(COX)inhibitors.The majority of natural COX inhibitors could be used as a selective therapeutic agent for complementary medicine and clinical applications.Currently,the inflammation is commonly treated by non-steroidal anti-inflammatory drugs(NSAIDs),several medications of which,however,have been linked to renal and gastrointestinal side effects.A variety of inhibitors of COX-2 that are selective(celecoxib,rofecoxib,valdecoxib and others)have been designed as NSAIDs mostly with enhanced stomach safety profiles.This helps to improve the compliance and functions in the geriatric patients as they have so many complications and problems associated with the diseases.The use of complementary medicine in combination with clinical therapy might give better results than medicine alone.Some disease condition like cancer which shows the COX-2 expressions could also have treatment related problems in such cases the selective inhibitors used as a complementary medicine.On the other hand,elevated cardiovascular risks have brought increasing worries about the safety of using specific inhibitors of COX-2.This current review focuses on how quinoline heterocycle was used for creation of inhibitors of COX-2 since 2009 along with its clinical significance in complementary medicine.These agents included the variety of substituents on the ring or ring attached to other heterocycles.As a result,the quinoline heterocycle will be used for creating and finding anti-inflammatory COX-2 medicines. 展开更多
关键词 QUINOLINE HETEROCYCLE INFLAMMATION CYCLOOXYGENASE Natural COMPLEMENTARY NSAID cox-2 inhibitor
原文传递
次苷酸查尔酮对LPS诱导的RAW264.7细胞iNOS和COX-2表达的影响
18
作者 王萌 高盼微 +4 位作者 罗子娟 常惠琳 张玥 袁庆 柴丽娟 《中国药理学通报》 CAS CSCD 北大核心 2024年第2期397-399,共3页
补骨脂为豆科植物补骨脂(Psoraleacorylifolia L.)果实,具有温肾助阳、温脾止泻的功效[1],临床上被用于治疗皮肤病、肾炎、骨折等[2-3]。次苷酸查尔酮(corylifol A,CYA)是中药补骨脂的活性成分之一,是一种异黄酮类化合物,具有抗炎、抗... 补骨脂为豆科植物补骨脂(Psoraleacorylifolia L.)果实,具有温肾助阳、温脾止泻的功效[1],临床上被用于治疗皮肤病、肾炎、骨折等[2-3]。次苷酸查尔酮(corylifol A,CYA)是中药补骨脂的活性成分之一,是一种异黄酮类化合物,具有抗炎、抗菌、抗氧化、抗骨质疏松的特性[4-5]。有研究表明,CYA能明显抑制破骨细胞的分化,且能明显降低LPS诱导的巨噬细胞一氧化氮(NO)的生成[6-7]。 展开更多
关键词 次苷酸查尔酮 RAW264.7 脂多糖 INOS cox-2 NO
下载PDF
选择性COX-2抑制剂引起心血管风险的研究进展
19
作者 黄勇 李頔 +3 位作者 王娜 冉娅娟 雷筱梅(综述) 钱妍(审校) 《西南医科大学学报》 2024年第1期87-92,共6页
非甾体抗炎药(non-steroid anti-inflammatory drugs,NSAIDs)是一种有效的、广泛使用的抗炎镇痛药物,其对环氧合酶(cyclo-oxygenase,COX)亚型(COX-1、COX-2)的抑制作用将引起不同的反应,选择性COX-2抑制剂将显著增加不良心血管事件的风... 非甾体抗炎药(non-steroid anti-inflammatory drugs,NSAIDs)是一种有效的、广泛使用的抗炎镇痛药物,其对环氧合酶(cyclo-oxygenase,COX)亚型(COX-1、COX-2)的抑制作用将引起不同的反应,选择性COX-2抑制剂将显著增加不良心血管事件的风险,随着此类药物使用的增加和临床循证证据的积累,其带来的心血管风险引起了越来越多学者的关注。笔者通过归纳分析最新发表文献对选择性COX-2抑制剂引起心血管风险的研究进行综述,以期辅助临床合理用药,减少不良反应,提高用药安全性。 展开更多
关键词 非甾体类抗炎药 环氧合酶 选择性环氧合酶-2抑制剂 心血管风险
下载PDF
黑逍遥散调控p38MAPK/ATF2/COX-2信号通路对阿尔茨海默病大鼠神经炎症的影响 被引量:3
20
作者 米彩云 彭超 +2 位作者 周君 李明成 王虎平 《中成药》 CAS CSCD 北大核心 2024年第2期590-595,共6页
目的 观察黑逍遥散对Aβ_(1-42)所致阿尔茨海默病(AD)大鼠学习记忆能力的影响,并从p38MAPK/ATF2/COX-2信号通路介导的炎症级联反应探讨其作用机制。方法 双侧海马注射1μL Aβ_(1-42)溶液复刻AD大鼠模型。筛选造模成功的大鼠50只,随机... 目的 观察黑逍遥散对Aβ_(1-42)所致阿尔茨海默病(AD)大鼠学习记忆能力的影响,并从p38MAPK/ATF2/COX-2信号通路介导的炎症级联反应探讨其作用机制。方法 双侧海马注射1μL Aβ_(1-42)溶液复刻AD大鼠模型。筛选造模成功的大鼠50只,随机分为模型组、盐酸多奈哌齐组(0.5 mg/kg)和黑逍遥散低、中、高剂量组(4.25、8.5、17 g/kg),连续给药42 d。Morris水迷宫实验检测定位航行与空间探索能力,HE染色观察海马神经元病理结构改变,ELISA法检测海马组织Aβ_(1-42)、iNOS、PGE_(2)表达,RT-qPCR法检测海马组织p38、ATF2、COX-2 mRNA表达,Western blot法检测海马组织p-p38、p-ATF2、COX-2蛋白表达。结果 与模型组比较,黑逍遥散中、高剂量组和盐酸多奈哌齐组逃避潜伏期缩短(P<0.01),有效区域运动距离、目标象限滞留时间百分比增加(P<0.01),海马CA1区神经元排列有序,胞体清晰,凋亡细胞减少,海马组织Aβ_(1-42)、iNOS、PGE_(2)水平降低(P<0.05,P<0.01),p38、COX-2 mRNA表达降低(P<0.05,P<0.01),p38、p-p38、p-ATF2、COX-2蛋白表达降低(P<0.01)。结论 黑逍遥散可改善Aβ_(1-42)所致AD大鼠的认知能力,其机制可能与阻断p38MAPK/ATF2/COX-2信号通路传导,进而减轻炎症反应有关。 展开更多
关键词 黑逍遥散 阿尔茨海默病 神经炎症 p38MAPK/ATF2/cox-2信号通路
下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部